FAS: PRICES FOR A NUMBER OF MEDICINES HAVE BEEN REDUCED BY AN AVERAGE OF 30%

In accordance with the rules of state registration and re-registration of prices for vital medicines (VED)*, in some cases, pharmaceutical companies must independently submit applications for price reduction. For example, when a manufacturer, after registering or re-registering the price of a medicine in Russia, reduces its cost abroad or if the first reproduced medicine loses its price advantage after the second and subsequent ones enter the market.

FAS controls the timeliness of submitting relevant applications from manufacturers. In case they do not submit an application, FAS issues a notification to the pharmaceutical company about the need to reduce the cost of the medicine. The manufacturers have 20 working days to reduce the price or give a written reasoned justification for the set price. Otherwise, FAS is obliged to make a decision to cancel the registered price, after which the sale of the medicine is prohibited at all stages of treatment.

This year, as part of the monitoring of medicine prices, FAS sent 21 notifications of a decrease in 51 registered maximum selling prices for VED**. For example, the cost of the in-demand medicine Lisinopril used for arterial hypertension, after reducing the marginal registration price by an average of 37%, decreased in pharmacies in Moscow from 196 rubles to 104 rubles (for the 5 mg release form No. 28) and from 760 rubles to 495 rubles (for the 20 mg release form No. 56).

FAS continues to monitor the fulfillment of the obligation to reduce the cost of medicines included in the list in these cases by manufacturers.

Reference:

*Included in the Decree of the Government of the Russian Federation dated 29.10.2010 №. 865 (ed. dated 18.11.2020) “On the State Regulation of Prices for Medicines Included in the List of Vital and Essential Medicines”.

**According to the results, pharmaceutical companies have reduced their prices by an average of 30%. Manufacturers provided justifications for the existing prices for 4 medicines. Prices for 4 more medicines were excluded from the register: for one of them - at the initiative of the manufacturer, for three more - due to the cancellation of prices by the service due to their non-reduction in due time.